Akero Therapeutics (AKRO) announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy. Most recently he served as VP, Commercial at Iovance Biotherapeutics (IOVA), where he was responsible for all pre-launch commercial activities for the first cell therapy for melanoma and cervical cancer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKRO:
- Akero completes enrollment in Phase 2b efruxifermin study for treatment of NASH
- Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
- Madrigal Pharmaceuticals price target raised to $325 from $175 at Evercore ISI
- Akero’s efruxifermin efficacy still compares favorably, says Morgan Stanley
- Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH